Exscientia started at Buy by 2 sell siders, at Neutral by 3rd

 

• BofA initiated coverage on Exscientia Plc 
  EXAI-8.43%+ Free Alerts
   with a Buy and $27 price target, implying a 25.5% upside.
• Analyst Michael Ryskin believes Exscientia stands out from other tech-enabled biotechs, as it uses AI to develop better drugs in a shorter period. 
• Ryskin adds that the company's lead compounds remain in the early Phase 1 trials as the platform validation continues.
• Goldman Sachs also initiated Exscientia with a Buy and $30 price target, suggesting a 39.5% upside. 
• Analyst Chris Shibutani believes the company is well-positioned to become a "pharmatech leader" in end-to-end artificial intelligence-enhanced drug discovery and development. 
• Exscientia's proprietary integration of advanced modeling and algorithmic learning could potentially result in better drug candidates & trials, more efficient development, and ultimately, higher probabilities of success, Shibutani tells investors.
• Morgan Stanley initiated coverage of Exscientia with an Equal Weight rating and a $25 price target, implying a 16% upside.
• Analyst Vikram Purohit says that Exscientia's platform "appears highly productive," and recent partnerships provide "significant validation of the company's AI-guided approach."
• But, Purohit prefers to remain on the sidelines as he awaits updates from the company's lead pipeline programs. 
• The company's most advanced programs: EXS21546 (Phase 1 study) and EXS617 (preclinical development), could have utility in indications such as lung & breast cancer. The analyst estimates about $1.5 billion in peak economic contribution to Exscientia.
• Earlier this month, Exscientia debuted on NASDAQ.

https://www.benzinga.com/analyst-ratings/analyst-color/21/10/23566243/three-analysts-initiate-coverage-on-this-ai-based-pharmatech